Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis

Study summary

RATIONALE: Losartan may be effective in treating patients with idiopathic pulmonary fibrosis. PURPOSE: This clinical trial is studying the side effects of losartan and to see how well it works in treating patients with idiopathic pulmonary fibrosis.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedlosartan

The study team can explain what participation involves.

Who it may be forPrecancerous Condition

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 21, 2021 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?University of South Florida

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Not applicable
Sponsor: University of South Florida
Interventions being studied: Drug: losartan

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Age \> 21 years
Diagnosis of idiopathic pulmonary fibrosis
Patients taking Coumadin and/or N-acetylcysteine may participate in the study
Baseline forced vital capacity (FVC) must be greater than or equal to 50%
Baseline 6 minute walk test distance walked must be greater than or equal to 200 meters not requiring greater than 6 lpm of oxygen

Reasons someone may not be able to joinExclusion criteria

Pregnant, intending to become pregnant or breastfeeding
Current or previous smoker of cigarettes or marijuana that recently quit within the last 6 months prior to enrollment
Allergy or allergic reaction to Losartan or any other angiotensin II receptor blocker
Taking losartan or any other angiotensin II receptor blocker
Baseline systolic blood pressure \< 100 mmHg
Currently taking or has taken immunosuppressant agents within the last month such as azathioprine, cyclophosphamide, colchicine and/or prednisone
History of lung transplant
History of kidney failure or liver disease
Inability to attend clinic visits

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of CincinnatiCincinnati, Ohio

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 21, 2021. Always confirm current availability with the study team.

View original record ↗